1-3 of 3
Emily Lederer
Close
Sort by
Journal Articles

Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma

Clinical Trials & Observations
Ashraf Badros, Elizabeth Hyjek, Ning Ma, Alexander Lesokhin, Ahmet Dogan, Aaron P. Rapoport, Mehmet Kocoglu, Emily Lederer, Sunita Philip, Todd Milliron, Cameron Dell, Olga Goloubeva, Zeba Singh
Journal: Blood
Blood (2017) 130 (10): 1189–1197.
https://doi.org/10.1182/blood-2017-03-775122
Published: 2017
Includes: Supplemental data
Journal Articles

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

Ashraf Z Badros, MD, Elizabeth Hyjek, MD PhD, Ning Ma, Alexander M. Lesokhin, MD, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Emily Lederer, RN, Sunita Philip, MBBS, Patricia Lesho, Ashlee Johnson, Cameron Dell, Olga Goloubeva, PhD, Zeba Singh, MD
Journal: Blood
Blood (2016) 128 (22): 490.
https://doi.org/10.1182/blood.V128.22.490.490
Published: 2016
Journal Articles

A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Ashraf Z. Badros, MD, Mehmet H. Kocoglu, MD, Ning Ma, NP, Aaron P. Rapoport, MD, Emily Lederer, RN, Sunita Philip, MBBS, Patricia Lesho, Cameron Dell, Nancy M. Hardy, MD, Jean Yared, MD, Olga Goloubeva, PhD, Zeba Singh, MD
Journal: Blood
Blood (2015) 126 (23): 506.
https://doi.org/10.1182/blood.V126.23.506.506
Published: 2015